ERIC 2018 | CLL treatment duration and the role of MRD

Peter Hillmen

One of the current debates in chronic lymphocytic leukemia (CLL), is whether novel agents should be used indefinitely or for fixed durations, and, if so, what should be used to determine the decision to cease and restart therapy. Here, Peter Hillmen, MD, ChB, of Leeds Teaching Hospital NHS Trust, Leeds, UK, gives his insight into this issue and the role of measurable residual disease (MRD) testing. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

Share this video